Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
03.02.2026 16:39
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says
03.02.2026 16:18
Johnson & Johnson's (JNJ) solid financial position and robust fundamentals will likely mitigate the
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
03.02.2026 15:00
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible." to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
03.02.2026 11:59
PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible." to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why
03.02.2026 09:34
Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher […]
ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story
03.02.2026 02:10
New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months
02.02.2026 13:00
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r
Johnson & Johnson’s Myeloma Approval And What It May Mean For JNJ Stock
01.02.2026 05:07
Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex...
Jim Cramer GE Vernova Has “Visibility on the Earnings to the 2030s”
31.01.2026 13:48
GE Vernova Inc. (NYSE:GEV) is one of the stocks that Jim Cramer shared takes on, along with navigating market shortages. Cramer highlighted the company’s long-term prospects, as he said: We’re a nation short on power, too. For years, our electricity barely grew, so power generation became a tough business, bad business. Biggest company, General Electric, […]
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?
31.01.2026 03:38
Johnson & Johnson is a picture of stability.
Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results
29.01.2026 17:45
Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January 22, Scotiabank lifted its price target on Johnson & Johnson (NYSE:JNJ) to $265 from $230. The firm reiterated an Outperform rating after the company’s Q4 results. The bigger takeaway was how well J&J […]
This Winning Fund Pro Likes J&J, Lowe’s, and Utility Stocks
29.01.2026 17:42
Susan Bao’s large-cap JPMorgan fund has outperformed the S&P 500 over many years. She’s bullish on stocks, focused on bargains.
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
29.01.2026 16:52
Halozyme Therapeutics' shares jump nearly 4% after preliminary 2025 results beat expectations and management lifts 2026 outlook.
Johnson & Johnson Stock Rises After Morgan Stanley Upgrade
29.01.2026 12:12
Johnson & Johnson Stock Advances on New Overweight Rating
Questex Presents the 10th Annual Patients as Partners® in Clinical Trials Europe Conference
29.01.2026 09:00
Patients as Partners® Europe now part of Questex’s Fierce Life Sciences, brings pharma R&D and patient advocacy together in an international event this May 19-20 in LondonNEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Today, Questex announced the keynotes and topics for the 10th annual Patients as Partners® Europe conference happening May 19-20, 2026 at the Royal National Hotel, in London, UK. Sanofi, Johnson and Johnson, Roche and Parexel kick off the conference together with patient advocacy on h
The Zacks Analyst Blog Johnson & Johnson, Netflix, Arista Networks, Omega and AXIL
29.01.2026 08:55
Johnson & Johnson leads Zacks' latest Analyst Blog as new research highlights earnings beats, growth drivers, and risks across major and micro-cap stocks.
How A New Price Target Is Rewriting The Story For Johnson & Johnson (JNJ)
27.01.2026 08:07
What a Changing Price Target Signals for Johnson & Johnson The recent shift in analysts' price target for Johnson & Johnson puts fresh attention on how the market is reassessing the stock's risks, opportunities, and overall narrative. With the target no longer sitting where it once did, the change itself becomes a key data point in how sentiment is being reset around the company. Stay tuned to see how you can keep on top of these price target moves and the evolving story behind them. Stay...
J&J Snack Foods CEO Dan Fachner on Dippin’ Dots Acquisition: ICR Conference 2026
26.01.2026 19:37
Exec Edge hosted a fireside chat at the ICR Conference 2026 with Dan Fachner, Chief Executive Officer, President and Chairman at J&J Snack Foods Corp. (Nasdaq: JJSF). The in-person interview was joined by Editor-at-Large Jarrett Banks, and they discussed the company’s more than 30 strategic acquisitions including the Dippin’ Dots acquisition, how J&J is positioning itself […]
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
26.01.2026 14:00
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.